97,451 Shares in Vaxcyte, Inc. $PCVX Purchased by Legal & General Group Plc

Legal & General Group Plc bought a new position in shares of Vaxcyte, Inc. (NASDAQ:PCVX) during the 2nd quarter, according to its most recent 13F filing with the Securities and Exchange Commission (SEC). The institutional investor bought 97,451 shares of the company’s stock, valued at approximately $5,665,000.

A number of other hedge funds also recently added to or reduced their stakes in PCVX. Smartleaf Asset Management LLC boosted its stake in shares of Vaxcyte by 156.2% during the 4th quarter. Smartleaf Asset Management LLC now owns 597 shares of the company’s stock worth $27,000 after acquiring an additional 364 shares in the last quarter. Caitong International Asset Management Co. Ltd boosted its position in Vaxcyte by 1,463.4% during the fourth quarter. Caitong International Asset Management Co. Ltd now owns 641 shares of the company’s stock worth $30,000 after purchasing an additional 600 shares in the last quarter. EverSource Wealth Advisors LLC boosted its position in Vaxcyte by 33.0% during the fourth quarter. EverSource Wealth Advisors LLC now owns 741 shares of the company’s stock worth $34,000 after purchasing an additional 184 shares in the last quarter. CIBC Private Wealth Group LLC grew its holdings in Vaxcyte by 22,500.0% in the third quarter. CIBC Private Wealth Group LLC now owns 1,356 shares of the company’s stock valued at $49,000 after purchasing an additional 1,350 shares during the last quarter. Finally, Capital Advisors Ltd. LLC purchased a new position in shares of Vaxcyte in the first quarter valued at $58,000. 96.78% of the stock is owned by hedge funds and other institutional investors.

Analyst Upgrades and Downgrades

PCVX has been the subject of several research reports. Zacks Research raised Vaxcyte from a “strong sell” rating to a “hold” rating in a research note on Wednesday, August 12th. Weiss Ratings restated a “sell (d-)” rating on shares of Vaxcyte in a report on Monday, July 6th. Finally, Wall Street Zen upgraded shares of Vaxcyte from a “strong sell” rating to a “sell” rating in a research report on Saturday, August 8th. Five investment analysts have rated the stock with a Buy rating, two have issued a Hold rating and one has issued a Sell rating to the company’s stock. According to MarketBeat, the stock has an average rating of “Moderate Buy” and a consensus price target of $86.00.

Insider Activity

In other news, CEO Grant Pickering sold 2,000 shares of the business’s stock in a transaction that occurred on Monday, July 27th. The shares were sold at an average price of $55.65, for a total value of $111,300.00. Following the completion of the transaction, the chief executive officer owned 133,215 shares of the company’s stock, valued at $7,413,414.75. The trade was a 1.48% decrease in their ownership of the stock. The transaction was disclosed in a filing with the SEC, which is available at the SEC website. The transaction was executed under a pre-arranged Rule 10b5-1 trading plan. Also, COO Jim Wassil sold 3,477 shares of the company’s stock in a transaction that occurred on Tuesday, September 1st. The shares were sold at an average price of $61.07, for a total transaction of $212,340.39. Following the transaction, the chief operating officer directly owned 155,041 shares in the company, valued at $9,468,353.87. The trade was a 2.19% decrease in their position. The SEC filing for this sale provides additional information. The sale was made to cover tax withholding obligations related to the vesting of equity awards. In the last ninety days, insiders have sold 121,873 shares of company stock valued at $6,671,730. 3.30% of the stock is owned by corporate insiders.

Vaxcyte Stock Down 0.7%

PCVX opened at $61.17 on Friday. The firm has a market cap of $9.10 billion, a P/E ratio of -8.02 and a beta of 1.22. The business’s fifty day simple moving average is $58.13 and its 200 day simple moving average is $56.17. Vaxcyte, Inc. has a 52 week low of $30.81 and a 52 week high of $65.00.

Vaxcyte (NASDAQ:PCVX) last announced its earnings results on Wednesday, August 5th. The company reported ($1.97) earnings per share for the quarter, beating the consensus estimate of ($2.06) by $0.09. During the same quarter last year, the company posted ($1.22) earnings per share. As a group, equities analysts expect that Vaxcyte, Inc. will post -7.6 EPS for the current fiscal year.

Vaxcyte Company Profile

Vaxcyte, Inc (NASDAQ: PCVX) is a clinical-stage biotechnology company focused on developing a new generation of preventive vaccines aimed at combating serious bacterial diseases. Headquartered in San Carlos, California, Vaxcyte leverages proprietary conjugation technologies to design and manufacture multivalent vaccines targeting pathogens for which there remain significant unmet medical needs. The company’s platform is intended to streamline the production of conjugate vaccines by improving antigen presentation and broadening strain coverage compared with conventional approaches.

Vaxcyte’s lead candidate, VAX-24, is a 24-valent pneumococcal conjugate vaccine designed to protect against 24 serotypes of Streptococcus pneumoniae.